Interpretation, context, and actionability: Navigating low-level ctDNA positives

Upcoming webinar

Interpretation, context, and actionability:

Navigating low-level ctDNA positives

Date: Friday, July 24, 2026

Time: 12:00 PM PT | 3:00 PM ET

Webinar duration: 30 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

In this webinar our subject matter experts plan to:

Describe the clinical significance of low-level ctDNA positivity and distinguish scenarios where the result may represent true molecular residual disease versus analytical noise.
Apply a framework for interpreting low-level Signatera™ results in the context of tumor type, treatment history, and timing of the assay across a pan-tumor patient population.
Discuss actionability strategies for low-level positive results, including the role of confirmatory testing, imaging correlation, and multidisciplinary tumor board discussion.

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:

Chirag Shah, MD

Gynecologic Oncologist

Kevin Manage, PhD

Oncology MSL Manager, Natera

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy